Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Common Equity: 2010-2024

Historic Common Equity for Altimmune (ALT) over the last 15 years, with Dec 2024 value amounting to $123.5 million.

  • Altimmune's Common Equity rose 39.16% to $185.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $185.6 million, marking a year-over-year increase of 39.16%. This contributed to the annual value of $123.5 million for FY2024, which is 36.37% down from last year.
  • According to the latest figures from FY2024, Altimmune's Common Equity is $123.5 million, which was down 36.37% from $194.1 million recorded in FY2023.
  • Altimmune's 5-year Common Equity high stood at $225.9 million for FY2020, and its period low was $123.5 million during FY2024.
  • In the last 3 years, Altimmune's Common Equity had a median value of $185.3 million in 2022 and averaged $167.6 million.
  • In the last 5 years, Altimmune's Common Equity soared by 396.21% in 2020 and then tumbled by 36.37% in 2024.
  • Over the past 5 years, Altimmune's Common Equity (Yearly) stood at $225.9 million in 2020, then fell by 11.84% to $199.1 million in 2021, then decreased by 6.95% to $185.3 million in 2022, then grew by 4.75% to $194.1 million in 2023, then tumbled by 36.37% to $123.5 million in 2024.